IDH2 and glioblastoma: Of 312 patients initially evaluated between 2016 and 2024, 218 patients with histologically confirmed IDH-wild-type glioblastoma (GBM) met inclusion criteria after excluding those with incomplete clinical, radiological, or biomolecular data.